Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,513 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HIgh Protein Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Pathobiology of Remission of Type 2 Diabetes

NCT03832725
View directory record Official record
Conditions
Newly Diagnosed Type 2 Diabetes, Obese
Interventions
High Protein (HP) weight loss diet, High carbohydrate (HC) weight loss diet
Other
Lead sponsor
University of Tennessee
Other
Eligibility
20 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

NCT06429059
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
Astaxanthin, Protandim, Melatonin, MitoQ
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115
View directory record Official record
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

NCT03115515
View directory record Official record
Conditions
Pregnancy Related, Thyroid
Interventions
levothyroxine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional

GVAX Plus Checkpoint Blockade in Neuroblastoma

NCT04239040
View directory record Official record
Conditions
Neuroblastoma, Pediatric Solid Tumor
Interventions
Tissue collection, GVAX vaccine, Nivolumab, Ipilimumab
Procedure · Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

NCT00805935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Infertility
Interventions
Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine

NCT03762291
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CVD908ssb-TXSVN
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

NCT04963413
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity

NCT00178646
View directory record Official record
Conditions
Stroke, Brain Injuries, Spasticity
Interventions
Botox
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
West Orange, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 1Phase 2 Interventional

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

NCT00119340
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

NCT00794820
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine Phosphate, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 1Phase 2 Interventional

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

NCT05123040
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

NCT01743950
View directory record Official record
Conditions
Glioma
Interventions
Bevacizumab, PRDR
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 2, 2026, 1:10 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)

NCT00001550
View directory record Official record
Conditions
Muscle Rigidity, Spasm, Stiff Man Syndrome
Interventions
IVIg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

NCT00001261
View directory record Official record
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome

NCT05034380
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Cardiovascular Diseases, Acute Exercise
Interventions
Acute exercise
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

NCT00669890
View directory record Official record
Conditions
Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Gemtuzumab Ozogamicin, Busulfan, Cyclophosphamide, Thymoglobulin, Tacrolimus, Mycophenolate Mofetil, Methotrexate
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

Brentuximab for Newly Diagnosed Hodgkin Disease

NCT02398240
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab
Drug
Lead sponsor
Mitchell Cairo
Other
Eligibility
1 Year to 29 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 2, 2026, 1:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT02166463
View directory record Official record
Conditions
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 22 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
182
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 1:10 PM EDT
Terminated Not applicable Interventional

Feeding Study in VLBW Premature Infants

NCT05744193
View directory record Official record
Conditions
VLBW - Very Low Birth Weight Infant
Interventions
Exempt Infant Formula
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
168 Days to 224 Days
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 2, 2026, 1:10 PM EDT